Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia

This study has been terminated.
(The primary outcome of this open clinical trial "Safety & Tolerability of MSC-Apceth" was achieved with the minimum number of patients needed.)
Sponsor:
Information provided by (Responsible Party):
Apceth GmbH & Co. KG
ClinicalTrials.gov Identifier:
NCT01351610
First received: May 10, 2011
Last updated: November 5, 2014
Last verified: November 2014

May 10, 2011
November 5, 2014
March 2011
October 2014   (final data collection date for primary outcome measure)
  • Collection of adverse events [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • Safety laboratory values [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • ECG findings [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Analysis of inflammation markers [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Evaluation safety and tolerability of the treatment with MSC-Apceth for Infusion and adverse events [ Time Frame: one year ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01351610 on ClinicalTrials.gov Archive Site
Comparison of course of haemodynamic and vascular processes [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia
Open, Randomized, Mono-Centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous Infusion of Human Bone Marrow Derived Autologous, CD34-Negative Mesenchymal Stem Cells for the Treatment of Critical Limb Ischemia in Patients With Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty

MSC_Apceth are GMP-manufactured, autologous ex-vivo expanded non-hemapoietic bone-marrow derived stem cells for the treatment of Critical Limb Ischemia

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Critical Limb Ischemia
  • Peripheral Artery Disease
  • Biological: PTA + Infusion of MSC_Apceth
    percutaneous transluminal angioplasty followed by infusion of MSC_Apceth
  • Procedure: PTA
    percutaneous transluminal angioplasty only
  • Experimental: Group B
    Intervention: Procedure: PTA
  • Experimental: Group A
    Intervention: Biological: PTA + Infusion of MSC_Apceth
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
30
December 2014
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with peripheral arterial occlusive disease (symptomatic PAOD), diagnosis of CLI defined as persistent, recurring ischemic rest pain for at least 2 weeks, and/or ulceration or gangrene of the foot or toe, with an ABPI </= 0.5,
  2. Patients with staging of ≥III according to Fontaine and ≥4 according to Rutherford categories,
  3. Patients fulfilling the criteria for an invasive re-vascularisation procedure (PTA) at the discretion of the investigator,
  4. Patients without major amputation of the lower extremities within the period of 6 months after inclusion in the opinion of the investigator,

Exclusion Criteria:

  1. Patients with wounds of a severity of greater than grade 2 on the Wagner Scale,
  2. Patients with life-threatening ventricular arrhythmia,
  3. Patients with unstable angina pectoris,
  4. Patients with severe congestive heart failure (i.e. NYHA Stage IV),
  5. Patients with uncontrolled hypertension (defined as diastolic blood pressure >110 mmHg or systolic blood pressure >180 mmHg during screening),
  6. Patients with an uncontrolled diabetes mellitus (HbA1c > 9%),
  7. Patients having any history of malignant tumour in the anamnesis or are currently on tumour treatment,
  8. Patients who are unsuitable for a MSC stem cell therapy in the opinion of the investigator,
Both
40 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01351610
MSC_Apceth_001
Yes
Apceth GmbH & Co. KG
Apceth GmbH & Co. KG
Not Provided
Principal Investigator: Peter Heider, MD, PhD Isar Medizin Zentrum, München
Apceth GmbH & Co. KG
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP